Solicitation for Written Comments on Proposed Objectives for Healthy People 2030; Correction, 62595 [2018-26299]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 233 / Tuesday, December 4, 2018 / Notices
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period. To
meet its burden, the petition must
comply with all the requirements of
§ 60.30, including but not limited to:
must be timely (see DATES), must be
filed in accordance with § 10.20, must
contain sufficient facts to merit an FDA
investigation, and must certify that a
true and complete copy of the petition
has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41–42, 1984.)
Petitions should be in the format
specified in 21 CFR 10.30.
Submit petitions electronically to
https://www.regulations.gov at Docket
No. FDA–2013–S–0610. Submit written
petitions (two copies are required) to the
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852.
Dated: November 28, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–26282 Filed 12–3–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Solicitation for Written Comments on
Proposed Objectives for Healthy
People 2030; Correction
Department of Health and
Human Services, Office of the Secretary,
Office of the Assistant Secretary for
Health, Office of Disease Prevention and
Health Promotion.
ACTION: Notice; correction.
AGENCY:
The Department of Health and
Human Services published a document
in the Federal Register of November 27,
2018, concerning request for comments
on the proposed Healthy People 2030
objectives. The document contained an
incorrect date.
FOR FURTHER INFORMATION CONTACT:
Ayanna Johnson, HP2030@hhs.gov.
SUMMARY:
Correction
In the Federal Register of November
27, 2018, in FR Doc. 2018–25836, on
pages 60876–60877, correct the ‘‘Dates’’
caption to read:
DATES: Written comments must be
submitted by January 17, 2019.
Dated: November 27, 2018.
Don Wright,
Deputy Assistant Secretary for Health
(Disease Prevention and Health Promotion).
[FR Doc. 2018–26299 Filed 12–3–18; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Substance Abuse and Mental Health
Services Administration
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; National Research Mentoring Network
(NRMN) U24 Center Applications.
Date: December 12, 2018.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, Room 3AN18, 45 Center
Drive, Bethesda, MD 20892.
Contact Person: Rebecca H. Johnson,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, Room 3AN18C, Bethesda,
MD 20892, 301–594–2771, johnsonrh@
nigms.nih.gov.
This notice is being published less
than 15 days prior to the meeting due
to the timing limitations imposed by the
review and funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
Dated: November 28, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–26281 Filed 12–3–18; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4150–32–P
VerDate Sep<11>2014
17:36 Dec 03, 2018
Jkt 247001
62595
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace.
FOR FURTHER INFORMATION CONTACT:
Charles LoDico, Division of Workplace
Programs, SAMHSA/CSAP, 5600
Fishers Lane, Room 16N02C, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITF) currently
certified to meet the standards of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory
Guidelines were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines were
initially developed in accordance with
SUMMARY:
E:\FR\FM\04DEN1.SGM
04DEN1
]]>Agencies
[Federal Register Volume 83, Number 233 (Tuesday, December 4, 2018)]
[Notices]
[Page 62595]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-26299]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Solicitation for Written Comments on Proposed Objectives for
Healthy People 2030; Correction
AGENCY: Department of Health and Human Services, Office of the
Secretary, Office of the Assistant Secretary for Health, Office of
Disease Prevention and Health Promotion.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services published a
document in the Federal Register of November 27, 2018, concerning
request for comments on the proposed Healthy People 2030 objectives.
The document contained an incorrect date.
FOR FURTHER INFORMATION CONTACT: Ayanna Johnson, [email protected].
Correction
In the Federal Register of November 27, 2018, in FR Doc. 2018-
25836, on pages 60876-60877, correct the ``Dates'' caption to read:
DATES: Written comments must be submitted by January 17, 2019.
Dated: November 27, 2018.
Don Wright,
Deputy Assistant Secretary for Health (Disease Prevention and Health
Promotion).
[FR Doc. 2018-26299 Filed 12-3-18; 8:45 am]
BILLING CODE 4150-32-P
